PEG modification enhances the in vivo stability of bioactive proteins immobilized on magnetic nanoparticles

Xu, Qing; Hou, Jing; Rao, Jun; Li, Guohao; Liu, Yunlong; Zhou, Jie

doi:10.1007/s10529-020-02867-4

Cited by 10 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3j). The negative charge on the surface of NPs has better stability in circulatory system in vivo [31,32]. The LE of PHBV-PTX-NPs, PDA-PHBV-PTX-NPs and RGD-PDA-PHBV-PTX-NPs were 21.48% ± 0.83%, 15.33% ± 0.74% and 14.21% ± 0.66%, respectively.…”

Section: Particle Morphology Size and Zeta Potentialmentioning

confidence: 98%

pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

Chen

Zhang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

A limitation of current anticancer nanocarriers is the contradiction between multiple functions and favorable biocompatibility. Thus, we aimed to develop a compatible drug delivery system loaded with paclitaxel (PTX) for hepatocellular carcinoma (HCC) therapy. A basic backbone, PTX-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) PHBV nanoparticle (PHBV-PTX-NPs), was prepared by emulsion solvent evaporation. As a gatekeeper, the pH-sensitive coating was formed by self-polymerization of dopamine (PDA). The HCC-targeted arginine-glycine-aspartic acid (RGD)-peptide and PDA-coated nanoparticles (NPs) were combined through the Michael addition. Subsequently, the physicochemical properties of RGD-PDA-PHBV-PTX-NPs were characterized by dynamic light scattering-autosizer, transmission electron microscope, fourier transform infrared spectroscopy, differential scanning calorimetry, thermogravimetry and X-ray spectroscopy. As expected, the RGD-PDA-PHBV-PTX-NPs showed robust anticancer efficacy in a xenograft mouse model. More importantly, they exhibited lower toxicity than PTX to normal hepatocytes and mouse in vitro and in vivo, respectively. Taken together, these results indicate that the RGD-PDA-PHBV-PTX-NPs are potentially beneficial for easing conflict between multifunction and biocompatible characters of nanocarriers.

show abstract

Section: Particle Morphology Size and Zeta Potentialmentioning

confidence: 98%

pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

Chen

Zhang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…On the other hand, PEG modification can reduce the frequency and incidence of adverse events administered as well as improve drug efficacy and tolerance [21]. In addition, PEG can also increase the solubility and stability of proteins which is also beneficial for the production and storage of drugs [22,23].…”

Section: Polyethylene Glycol (Peg) and Peg Analogmentioning

confidence: 99%

Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy

Sun

Yang

2023

Polymers

View full text Add to dashboard Cite

Polymer-protein systems have excellent characteristics, such as non-toxic, non-irritating, good water solubility and biocompatibility, which makes them very appealing as cancer therapeutics agents. Inspiringly, they can achieve sustained release and targeted delivery of drugs, greatly improving the effect of cancer therapy and reducing side effects. However, many challenges, such as reducing the toxicity of materials, protecting the activities of proteins and controlling the release of proteins, still need to be overcome. In this review, the design of hybrid polymer–protein systems, including the selection of polymers and the bonding forms of polymer–protein systems, is presented. Meanwhile, vital considerations, including reaction conditions and the release of proteins in the design process, are addressed. Then, hybrid polymer–protein systems developed in the past decades for cancer therapy, including targeted therapy, gene therapy, phototherapy, immunotherapy and vaccine therapy, are summarized. Furthermore, challenges for the hybrid polymer–protein systems in cancer therapy are exemplified, and the perspectives of the field are covered.

show abstract

“…Covalent adsorptive attachment of PEG to the surface of nanoparticles results in in vivo circulation and favored deposition in tumorous and inflamed tissues [103]. At the same time, PEGylation increases the stability in biological fluids and reduces the aggregation of particles during storage and the in vivo application [104]. Aldayel et al developed a formulation for lipid-based siRNA NPs, taking advantage of the beneficial accumulation and targeting properties of PEG in inflamed tissues [105].…”

Section: Surface Design Optionsmentioning

confidence: 99%

Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies

Gabel

Knauss

Fischer

et al. 2022

IJMS

View full text Add to dashboard Cite

The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems.

show abstract

PEG modification enhances the in vivo stability of bioactive proteins immobilized on magnetic nanoparticles

Cited by 10 publications

References 35 publications

pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy

Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies

Contact Info

Product

Resources

About